Mónica Jorge Fernández

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers

Ana Fernández Montés, Nieves Martínez Lago, Marta Covela Rúa et al. · Cancer Medicine · 2019 · 37 citations · Full text

Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis

Ana Fernández Montés, Paula González Villarroel, Manuel Valladares Ayerbes et al. · Journal of Cancer Research and Therapeutics · 2017 · 24 citations · Full text

Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).

Rafael López‐López, Carlos Mendez‐Dorantes, Mónica Jorge Fernández et al. · PubMed · 2013 · 17 citations

Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

Jaime Feliú, Mónica Jorge Fernández, Teresa Macarulla et al. · Cancer Chemotherapy and Pharmacology · 2021 · 17 citations

Urology, Oncology, Pancreatic Cancer +7

Renal primary angiosarcoma

Bruno Lopez, Isaura Fernández Pérez, Jesús Álvarez et al. · Clinical & Translational Oncology · 2007 · 15 citations

Urology, Surgical Pathology, Renal Pathology +6